Tag: DapaCare

Detailed results from Phase III DAPA-HF trial showed FARXIGA significantly reduced both the incidence of cardiovascular death and the worsening of heart failure

Coronary/Structural Heart by 0 comments

DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes   September 1, 2019 – AstraZeneca today announced detailed results from the landmark Phase III […]

Continue Reading →